If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Radiofrequency Ablation Successful as Salvage Therapy After Hepatectomy Metastases: Presented at SIR By Thomas R. Collins TAMPA, Fla -- March 18, 2010 -- Radiofrequency ablation worked well to extend the lives of patients getting the procedure as salvage treatment after hepatectomy, researchers said here at the Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting. A review of 56 patients with 71 treated lesions found that the median overall survival rate was 31 months, said Constantinos Sofocleous, MD, PhD, Interventional Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York. “Radiofrequency ablation can be used to treat patients with colorectal liver metastases recurring after hepatectomy,” Dr. Sofocleous said in a presentation on March 15. The study involved a review of cases of hepatic colorectal metastases between December 2002 and December 2008. Researchers sought to evaluate radiofrequency ablation on patients who developed liver metastases after a hepatectomy. Twenty-four of the patients were female, and the median age at the time of radiofrequency ablation was 61. The average tumour size was 1.9 cm. Patients were assessed using computed tomography every 2 to 4 months to check for local tumour progression. For those with a clinical risk score of 0 to 2, the median survival was 35 months, with 98% surviving 1 year, 73% surviving 2 years, and 45% surviving 3 years. The median time of survival without local tumour progression was 16 months for these patients. For those with a clinical risk score of 3 or 4, the median survival was 21 months, with 69% surviving 1 year, 42% surviving 2 years, and 28% surviving 3 years. The median time of survival without local tumour progression for this group was 5 months. There was a high rate of local tumour progression after a single ablation procedure among even the patients with lower clinical risk scores of 0 to 2, Dr. Sofocleous said. This was attributed to the aggressive nature of the treated tumours. More than half of the patients with local tumour progression after ablation had multifocal and extrahepatic progression of the disease, he said. “The combination of a low clinical risk score, surveillance with imaging, and repeat ablation to treat local tumour progression are associated with better oncological outcomes,” Dr. Sofocleous said. Hepatic arterial infusion chemotherapy might provide more benefits, he added. [Presentation title: Radiofrequency Ablation of Recurrent Colorectal Cancer Hepatic Metastases After Ablation. Abstract 107]
|
